Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Asia
Biotech
Ono pays $80M for local rights to trio of Biohaven IgG degraders
Japan’s Ono is paying $80 million upfront for regional rights to three of Biohaven’s IgG degraders, led by a phase 3-stage Grave’s disease prospect.
James Waldron
Oct 8, 2026 5:23am
TCGX launches $600M fund to bankroll Asian biotechs
Oct 7, 2026 10:21am
Fierce Pharma
Novartis pledges nearly $480M to bolster China production, R&D
Mar 23, 2026 10:35am
Hansoh, Chugai ink separate and lucrative licensing agreements
Oct 17, 2025 11:04am
Nasdaq plans 24-hour trading for US
Mar 7, 2025 12:32pm
CRO and clinical trial markets set for growth by 2030: reports
Dec 4, 2024 3:15pm
